IAG Bio-Partnering Team to Attend Anlgonordic in London, United Kingdom 24 May 2018
Dr. Olga Kubassova, CEO of IAG will attend Anglonordic in London, United Kingdom to discuss the increasing need for collaboration between the investors and biotechnology companies in development of new compounds and to introduce IAG’s platforms, targeted development strategies and risk-sharing business model.
IAG Bio-Partnering division is an independent investment division of IAG that works to build a diversified investment portfolio of innovative life science companies at various stages of clinical development.
IAG biotech portfolio companies take advantage of a range of innovative R&D solutions, risk-sharing financing and partnership models, early visibility of study performance through DYNAMIKA platform and tailored strategy for potential pharmaceutical partnerships.
The scope of discussions for this conference include:
– Development of clinical stage assets
– IP acquisition from the academic partners and biotech companies
– Investment partnerships
– Strategic collaborations
To find out more about IAG Bio-Partnering services or to schedule a meeting during Bio€quity, please send an email to email@example.com.
Anglonordic is the only life science conference in the UK that is exclusively for European investors and R&D companies from the Nordics and the UK to connect with each other. The Anglonordic Life Science Conference has a “by-invitation-only” policy. The organisers welcome a limited number of service suppliers as sponsors or exhibitors. The main conference room has a biotech investment focus; the technology room features devices, diagnostics, delivery and development tools. One-to-one meetings take place throughout the day. The Exhibition and quiet area double up for lunch service and refreshments are available all day. To find out more about the conference click here
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: firstname.lastname@example.org
Follow the Company: Linkedin